to be fair, page-35

Has it not occurred to anyone that perhaps the reason MR and co. do not provide up to the minute details of every permutation imaginable as regards a Nasdaq listing might be that:

A. the company has bigger fish to fry.
B. they are not as enamoured of a Nasdaq listing as some seem to be expressing.
C. they are not as immediately expectant of instantaneous and dramatic results as some seem to be hoping.
D. the company has other ways of attracting attention to its patented technology other than a Nasdaq listing.
E. a Nasdaq listing didn't stop Cephalon from devouring 20% of Mesoblast, moving it's SP from around $3 to over $9 in around 6 months.
F. Nasdaq listings don't work for all companies (biotech or otherwise), most give up due to the expense and time requirements needed.

Chemgenex is one example of this:

The voluntary decision to de-list from NASDAQ and to deregister was taken following a detailed review of the limited benefits generated by the listing as compared to the significant, and growing, compliance costs of maintaining it. In order to maintain the current NASDAQ listing, the Company is required to devote disproportionately large amounts of management time to meet numerous reporting and compliance obligations, such as the preparation and filing of periodic reports, Annual Reports on Form 20-F and compliance with burdensome control issues at great expense. Based on this, ChemGenex no longer sees sufficient value in maintaining its secondary Level 2 listing on NASDAQ.

In conclusion, and IMHO, MR and co. have done everything in their power to keep the market informed of the company's progress.

To do more would represent an inordinate amount of time devoted to something which may have as much effect as putting your finger in a glass of water and lifting it back up again.

Phase Three success and commensurate FDA approval will blow any effect a Nasdaq listing might have to the shizenhousen.

Pardon my French.